B cells from Patients with Rheumatoid Arthritis Show Conserved CD39-Mediated Regulatory Function and increased CD39 Expression After Positive Response to Therapy.

Szczegóły
Abstrakt

Tytuł:: B cells from Patients with Rheumatoid Arthritis Show Conserved CD39-Mediated Regulatory Function and increased CD39 Expression After Positive Response to Therapy.
Autorzy:: Zacca ER; Laboratorio de Inmunología. Hospital Nacional de Clínicas (HNC), Universidad Nacional de Córdoba (UNC), Córdoba, Argentina.
Amezcua Vesely MC; Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Facultad de Ciencias Químicas, UNC, Córdoba, Argentina.
Ferrero PV; Laboratorio de Inmunología. Hospital Nacional de Clínicas (HNC), Universidad Nacional de Córdoba (UNC), Córdoba, Argentina.
Acosta CDV; Laboratorio de Inmunología. Hospital Nacional de Clínicas (HNC), Universidad Nacional de Córdoba (UNC), Córdoba, Argentina.
Ponce NE; Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Facultad de Ciencias Químicas, UNC, Córdoba, Argentina.
Bossio SN; Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Facultad de Ciencias Químicas, UNC, Córdoba, Argentina.
Mussano E; Servicio de Reumatología. HNC, UNC, Córdoba, Argentina.
Onetti L; Servicio de Reumatología. HNC, UNC, Córdoba, Argentina.
Cadile I; Servicio de Reumatología. HNC, UNC, Córdoba, Argentina.
Acosta Rodríguez EV; Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Facultad de Ciencias Químicas, UNC, Córdoba, Argentina.
Montes CL; Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Facultad de Ciencias Químicas, UNC, Córdoba, Argentina.
Gruppi A; Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Facultad de Ciencias Químicas, UNC, Córdoba, Argentina. Electronic address: .
Źródło:: Journal of molecular biology [J Mol Biol] 2021 Jan 08; Vol. 433 (1), pp. 166687. Date of Electronic Publication: 2020 Oct 22.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: Amsterdam : Elsevier
Original Publication: 1959- : London : Academic Press
MeSH Terms:: Immunomodulation*
Apyrase/*metabolism
Arthritis, Rheumatoid/*immunology
Arthritis, Rheumatoid/*metabolism
B-Lymphocytes/*immunology
B-Lymphocytes/*metabolism
Adenosine/metabolism ; Apyrase/genetics ; Arthritis, Rheumatoid/pathology ; Arthritis, Rheumatoid/therapy ; B-Lymphocytes, Regulatory/immunology ; B-Lymphocytes, Regulatory/metabolism ; Case-Control Studies ; Cytokines/biosynthesis ; Disease Management ; Disease Susceptibility ; Gene Expression ; Humans ; Lymphocyte Activation ; Lymphocyte Count ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Treatment Outcome
References:: Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):865-9. (PMID: 22423038)
Eur J Immunol. 2017 Jan;47(1):131-143. (PMID: 27800605)
Int Immunol. 2015 Oct;27(10):479-86. (PMID: 26071023)
Arthritis Rheumatol. 2018 Sep;70(9):1429-1439. (PMID: 29648684)
Bull NYU Hosp Jt Dis. 2006;64(1-2):12-5. (PMID: 17121483)
Int J Rheum Dis. 2018 Aug;21(8):1548-1556. (PMID: 30146748)
J Immunol. 2014 Dec 15;193(12):5904-13. (PMID: 25392527)
Cell Rep. 2013 Jun 27;3(6):1824-31. (PMID: 23770243)
Arthritis Res Ther. 2009;11(3):R84. (PMID: 19500335)
J Leukoc Biol. 2017 May;101(5):1263-1271. (PMID: 28193736)
Curr Opin Immunol. 2017 Jun;46:112-120. (PMID: 28538163)
Cancer Res. 2018 Sep 1;78(17):5175. (PMID: 30115702)
J Immunol Methods. 2003 Apr 1;275(1-2):251-5. (PMID: 12667688)
J Rheumatol. 1991 May;18(5):716-20. (PMID: 1650841)
Sci Rep. 2016 Oct 24;6:35804. (PMID: 27775097)
Arthritis Rheumatol. 2015 Feb;67(2):545-54. (PMID: 25418634)
Trends Immunol. 2016 Jul;37(7):427-439. (PMID: 27236363)
Lancet. 2016 Dec 3;388(10061):2763-2774. (PMID: 27863807)
Front Immunol. 2018 Oct 01;9:2241. (PMID: 30327652)
Int J Rheum Dis. 2015 May;18(4):421-32. (PMID: 24589014)
Trends Immunol. 2012 May;33(5):231-7. (PMID: 22487321)
Arthritis Rheumatol. 2014 Sep;66(9):2590-600. (PMID: 24909567)
Cell Biochem Funct. 2013 Jul;31(5):395-9. (PMID: 23070807)
Nat Rev Rheumatol. 2017 Jan;13(1):41-51. (PMID: 27829671)
Rheum Dis Clin North Am. 2009 Nov;35(4):745-57, vii-viii. (PMID: 19962619)
Biofactors. 2007;31(2):77-98. (PMID: 18806312)
Nat Med. 2015 Jun;21(6):638-46. (PMID: 26005855)
Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2097-103. (PMID: 22772752)
Oncoimmunology. 2016 Feb 26;5(2):e1082703. (PMID: 27057473)
Nat Immunol. 2013 Oct;14(10):1054-63. (PMID: 23995234)
Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2509-14. (PMID: 25675517)
Nat Commun. 2015 Jan 22;6:5997. (PMID: 25609381)
Trends Immunol. 2009 Mar;30(3):102-8. (PMID: 19201652)
Acta Biochim Pol. 2018;65(1):1-7. (PMID: 29360885)
Immunol Lett. 2019 Oct;214:55-64. (PMID: 31479688)
Arthritis Rheum. 1995 Jan;38(1):44-8. (PMID: 7818570)
AIDS. 2014 Jul 31;28(12):1749-58. (PMID: 24871455)
Arthritis Res Ther. 2011;13(6):R197. (PMID: 22146575)
J Exp Med. 2007 Jun 11;204(6):1303-10. (PMID: 17502663)
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S204-15. (PMID: 20176259)
Arthritis Rheumatol. 2014 Feb;66(2):273-83. (PMID: 24504799)
Arthritis Rheum. 2010 Sep;62(9):2569-81. (PMID: 20872595)
Ann Rheum Dis. 2018 Jul;77(7):1053-1062. (PMID: 29431119)
Blood. 2013 Jul 4;122(1):9-18. (PMID: 23678003)
Immunol Rev. 2017 Mar;276(1):121-144. (PMID: 28258700)
Trends Mol Med. 2013 Jun;19(6):355-67. (PMID: 23601906)
Grant Information:: R01 AI110340 United States AI NIAID NIH HHS; R01 AI116432 United States AI NIAID NIH HHS
Contributed Indexing:: Keywords: ADO pathway; Breg; CD39; Rheumathoid Arthritis; T-cell suppression
Substance Nomenclature:: 0 (Cytokines)
EC 3.6.1.5 (Apyrase)
EC 3.6.1.5 (ENTPD1 protein, human)
K72T3FS567 (Adenosine)
Entry Date(s):: Date Created: 20201025 Date Completed: 20210430 Latest Revision: 20220816
Update Code:: 20240105
PubMed Central ID:: PMC9376888
DOI:: 10.1016/j.jmb.2020.10.021
PMID:: 33098857
: Czasopismo naukowe

Full Text Finder

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by progressive joint destruction associated with increased pro-inflammatory mediators. In inflammatory microenvironments, exogenous ATP (eATP) is hydrolyzed to adenosine, which exerts immunosuppressive effects, by the consecutive action of the ectonucleotidases CD39 and CD73. Mature B cells constitutively express both ectonucleotidases, converting these cells to potential suppressors. Here, we assessed CD39 and CD73 expression on B cells from treated or untreated patients with RA. Neither the frequency of CD73 + CD39 + and CD73 - CD39 + B cell subsets nor the levels of CD73 and CD39 expression on B cells from untreated or treated RA patients showed significant changes in comparison to healthy controls (HC). CpG+IL-2-stimulated B cells from HC or untreated RA patients increased their CD39 expression, and suppressed CD4 + and CD8 + T cell proliferation and intracellular TNF-production. A CD39 inhibitor significantly restored proliferation and TNF-producing capacity in CD4 + T cells, but not in CD8 + T cells, from HC and untreated RA patients, indicating that B cells from untreated RA patients conserved CD39-mediated regulatory function. Good responder patients to therapy (R-RA) exhibited an increased CD39 but not CD73 expression on B cells after treatment, while most of the non-responder (NR) patients showed a reduction in ectoenzyme expression. The positive changes of CD39 expression on B cells exhibited a negative correlation with disease activity and rheumatoid factor levels. Our results suggest modulating the ectoenzymes/ADO pathway as a potential therapy target for improving the course of RA.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Informacja